BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
210 hedge funds and large institutions have $4.24B invested in bluebird bio in 2017 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 56 increasing their positions, 80 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
210
Holders Change
+11
Holders Change %
+5.53%
% of All Funds
5.24%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
37
Increased
56
Reduced
80
Closed
18
Calls
$60M
Puts
$35.1M
Net Calls
+$24.8M
Net Calls Change
+$18.6M
Top Buyers
| 1 |
BlackRock
New York
|
+$289M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$43.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$25.2M |
| 4 |
PC
PointState Capital
New York
|
+$15.3M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$13M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.2M |
| 2 |
DM
Deerfield Management
New York
|
-$17.7M |
| 3 |
AG
Artal Group
Luxembourg
|
-$15.7M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$13.1M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$11.6M |
